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Abstract
Since inflammation has been linked to carcinogenic events, discovery of relevant biomarkers may have important
preventative implications. Procalcitonin (ProCT) has been shown to be an important prognostic biomarker in severe
inflammatory conditions, but there is no data regarding its biomarker role, if any, beyond the acute phase. In a
recent study published in BMC Medicine, Cotoi et al. analyzed whether serum ProCT levels in healthy individuals are
associated with mortality outcomes. The results are affirmative in that baseline ProCT was shown to be strongly and
independently associated with all-cause and cancer mortality and with the incidence of colon cancer in men. By
contrast, the study indicated that high sensitivity C-reactive protein was independently associated with
cardiovascular mortality but not with cancer mortality in men. Thus, baseline levels of ProCT appear to have
prognostic biomarker implications potentially related to its emerging biomediator action(s).
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Procalcitonin
Procalcitonin (ProCT) is the prohormone of the peptide
calcitonin normally produced by C cells of the thyroid
gland and by certain neuroendocrine cells in the lung.
However, in response to bacterial and/or severe systemic
inflammatory exposure, cells throughout the body se-
crete ProCT and its associated peptides (Table 1) [1]. In
addition to this biomarker role in septic-like conditions,
ProCT also appears to act as a biomediator, whereby it
has direct and independent toxic effects on cells [2,3].
Although there has been ample documentation that
serum ProCT increases multifold in various septic-like
conditions, where it correlates with severity and morta-
lity [1,4,5], there has been little attention drawn to the
possible influence of baseline ProCT and its associated
peptides that circulate at low concentrations in healthy
individuals [6].
The Malmo Diet and Cancer Cohort
A recent study published in BMC Medicine by Cotoi
et al. observed the effects of ProCT on all-cause and
cancer mortality in healthy individuals [7]. The Malmo
Diet and Cancer Cohort is a large longitudinal prospective
population study initiated to determine dietary habits and
genetic markers that could predict the incidence of can-
cers in the general population, and to investigate car-
diovascular risk factors and early atherosclerosis using
three national registries with validated outcomes. Of the
28,449 individuals enrolled in the Malmo Diet and
Cancer Cohort, 6,094 were part of the cardiovascular
arm of the study. Individuals previously diagnosed with
coronary disease or stroke and individuals with previous
diagnoses of cancer were excluded from the study.
Plasma measurements for ProCT were available for
3,322 participants. In a previous study by these inves-
tigators using the same cohort, there was a positive
association between plasma levels of ProCT and the in-
cidence of coronary events and deaths in healthy indi-
viduals [8]. However, following appropriate statistical
adjustments, ProCT was not an independent predictor
of cardiovascular risk. Although ProCT is a recognized
biomarker, it’s scope of utility has expanded in the re-
cent past to include aspects beyond the acute phase it-
self. The current study by Cotoi et al. recognized that
the baseline levels of ProCT might have prognostic fea-
tures possibly different from those of other biomarkers,
such as C-reactive protein [7].
* Correspondence: enylen@gmail.com
Department Endocrinology, VAMC, and George Washington University
School of Medicine, Washington, DC, USA
© 2013 Panico and Nylen; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Panico and Nylen BMC Medicine 2013, 11:189
http://www.biomedcentral.com/1741-7015/11/189
Procalcitonin and cancer mortality
In the study by Cotoi et al., adjusted baseline ProCT
was strongly associated with the risk of all-cause and
cancer mortality and with incidence of colon cancer in
men [7]. The cumulative incidence of all-cause mortality
increased by quartile of baseline ProCT levels. By con-
trast, high sensitivity C-reactive protein was indepen-
dently associated with cardiovascular mortality but not
with cancer mortality in men. Neither biomarker corre-
lated with incident mortality in women. A significant
correlation was, however, found between ProCT quar-
tiles and cystatin C, confirming previous data showing
that renal function influences plasma levels of ProCT
[6]. Although these results are of considerable interest,
one important caveat is the assay applied. The assay
used for ProCT measurements in the study has its lower
detection limit at 10 pg/mL (ProCa-S; BRAHMS GmbH,
Hennigsdorf, Germany). This is considered a sensitive
assay, but the levels of baseline ProCT obtained, espe-
cially in women, are at or below the functional perfor-
mance of the assay, weakening the overall reliability. As
shown in Table 1, ProCT consists of additional peptides
other than the intact prohormone itself. For example,
the baseline levels of the amino portion of ProCT, which
is not detected by the authors’ assay, exceed that of cal-
citonin and the other peptides, and may therefore yield
more accurate information [6].
Potential pathological pathways
Although the underlying mechanisms linking ProCT
with carcinogenesis are unclear, in the context of the
study by Cotoi et al. [7], there are several pathological
pathways that may have relevance with respect to ProCT
(Figure 1).
Procalcitonin and cytokines
The specific stimuli for ProCT secretion are not well
understood although proinflammatory cytokines such as
tumor necrosis factor, and IL-1beta have been reported
to stimulate ProCT secretion [1]. Moreover, it is known
that ProCT induces upregulation of inflammatory cyto-
kines in in vitro and in vivo studies [2,3,9]. Some of
these cytokines are an important link between inflam-
mation and carcinogenesis [10-15]. In particular, IL-6
seems to positively correlate to ProCT levels in various
pathological conditions [1,2]. Elevated expression of IL-6
has been detected in various epithelial tumors [16]. Fur-
thermore, several studies implicate IL-6 as a critical me-
diator of mammary stem cell renewal in both normal
and tumor contexts [17].
Procalcitonin and reactive oxygen species
Various stimuli lead to generation of reactive oxygen
species. For example, inducible nitric oxide synthase is as-
sociated with cytotoxicity via formation of iron-nitrosyl
complexes and inactivation of iron-containing enzymes
[18] and may play a role in tumor growth and metastasis
[19,20]. Araujo et al. observed that inducible nitric oxide
synthase is upregulated after the application of ProCT in
mesangial cells [2], suggesting that increases in ProCT can
be linked to an increase in reactive oxygen species, which
in turn has been associated with cancers such as colon
cancer [21].
Procalcitonin and the Wnt pathway
The Wnt pathway has emerged as a critical pathway in
several aspects of carcinogenesis [22-24], including aber-
rant activation in colorectal cancer [25]. Interestingly,
the Wnt pathway is significantly upregulated by the ap-
plication of ProCT [2], suggesting another route for
ProCT to carcinogenesis.
Procalcitonin and DNA methylation
Alterations in circulating DNA can be found in patients
with various malignancies, and methylation patterns of
serum DNA seem to correlate with clinical presentation
Table 1 The ratio of baseline procalcitonin and its





Calcitonin carboxyl-terminus peptide-1 1.7
Figure 1 Hypothetical mechanism(s) through which
procalcitonin might work as a toxic biomediator.
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and outcome in patients with cancer [15,26]. Interes-
tingly, ProCT correlates with DNA methylation not only
in patients with cancer but also those with chronic kid-
ney disease [27].
Discussion
The results of the study by Cotoi et al. highlight novel
aspects of ProCT beyond the well-documented acute
phase response [1,7]. The fact that ProCT presented
a different association pattern from high sensitivity
C-reactive protein suggests that ProCT is a biomarker of
specific inflammatory processes. Moreover, in the
present study, the authors show that after adjustment
for cystatin C the association between ProCT and
colon cancer in men remained statistically significant,
suggesting a specific relationship between cancer and
ProCT levels in spite of renal function. Further work is
required to determine the potential pathways through
which this effect may occur. The importance of the
study by Cotoi et al. is to uncover a potentially relevant
biomarker for early events in the carcinogenic process
and thereby enhance preventative strategies. However,
essentially nothing is currently known regarding baseline
physiological and pathophysiological variability in ProCT
or its associated peptides. Most likely, further optimi-
zation of the ‘ProCT’ assay would have to be achieved,
as discussed above, to establish if the results of Cotoi
et al. could be used clinically. Intriguingly, ProCT may
have a role as a biomediator considering its actions rele-
vant to carcinogenesis (Figure 1); future research may
also focus on means to alter ProCT action [28].
Conclusion
Cotoi et al. found an independent link between higher
baseline plasma ProCT levels in healthy men with subse-
quent mortality outcomes and colon cancer, suggesting
that subtle but subclinically elevated ProCT might have
prognostic implications. Although an epiphenomenon
cannot be excluded or causality be proven, the link could
be related to emerging biomediator properties of ProCT
that merit further scrutiny.
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